Editorial
Lettres de noblesse: the three milestones
August 24, 2012 | 10.4244/EIJV8I4A63
In pursuit of perfection: “alive and better” as the measure of procedural success
August 24, 2012 | 10.4244/EIJV8I4A64
Not all drug-eluting balloons are equally good for patients, not all patients are equally suitable for drug-eluting balloons
August 24, 2012 | 10.4244/EIJV8I4A65
Multivessel versus culprit-only revascularisation in ST elevation acute myocardial infarction: facts and criticism
August 24, 2012 | 10.4244/EIJV8I4A66
EAPCI column
The latest news about the ESCeL Platform
August 24, 2012 | 10.4244/EIJV8I4A67
Clinical research
Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates
August 24, 2012 | 10.4244/EIJV8I4A68
Improvement of physical and mental health after transfemoral transcatheter aortic valve implantation
August 24, 2012 | 10.4244/EIJV8I4A69
Comparison of two drug-eluting balloons: a report from the SCAAR registry
August 24, 2012 | 10.4244/EIJV8I4A70
Paclitaxel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study
August 24, 2012 | 10.4244/EIJV8I4A71
Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease
August 24, 2012 | 10.4244/EIJV8I4A72
Experimental research
Expert review
Technical report
Non-invasive fractional flow reserve: scientific basis, methods and perspectives
August 24, 2012 | 10.4244/EIJV8I4A79
How should I treat?
How should I treat a retrograde dissection of the aortic sinus of Valsalva during a percutaneous coronary intervention?
August 24, 2012 | 10.4244/EIJV8I4A80